Securities code: Zhejiang Ausun Pharmaceutical Co.Ltd(603229) securities abbreviation: Zhejiang Ausun Pharmaceutical Co.Ltd(603229) Announcement No.: 2022004 Zhejiang Ausun Pharmaceutical Co.Ltd(603229)
Announcement of abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips: \uf020
● Zhejiang Ausun Pharmaceutical Co.Ltd(603229) (hereinafter referred to as “the company”) shares traded on February 25, February 28 and March 1, 2022. The cumulative deviation of the closing price increase exceeds 20%, which belongs to the abnormal fluctuation of stock trading. \uf020
● after the company’s self-examination and written inquiry with the controlling shareholder and actual controller of the company, as of the disclosure date of this announcement, it is confirmed that there is no material information that should be disclosed but not disclosed.
1、 Details of abnormal fluctuations in stock trading
The company’s stock trading deviated from the closing price by more than 20% in three consecutive trading days on February 25, February 28 and March 1, 2022. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to abnormal fluctuation of stock trading.
2、 Relevant information concerned and verified by the company
In view of the abnormal fluctuation of the company’s shares, the company has checked the relevant matters, and now the relevant information is explained as follows:
(I) production and operation
According to the self-examination of the company, the current production and operation of the company is normal, and there is no major information that should be disclosed but not disclosed.
(II) major events
After the company’s self-examination and written inquiry and confirmation to the controlling shareholder and actual controller, as of the disclosure date of this announcement, there are no major events affecting the abnormal fluctuation of the company’s stock trading, and there are no other major events that should be disclosed but not disclosed, including but not limited to major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring Major events such as asset divestiture and asset injection.
(III) media reports, market rumors and hot concepts
The company recently paid attention to media reports and listed the company as covid-19 concept stock. After verification, the company has no covid-19 drug-related products at present.
The company has not found any other media reports or market rumors that may have a great impact on the company’s stock trading price, and has not found any other major information that may have a great impact on the company’s stock price.
(IV) other stock price sensitive information
The company verified that the controlling shareholders, actual controllers, directors, supervisors and senior managers of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Relevant risk tips
The closing price of the company’s shares deviated from the value by more than 20% in three consecutive trading days on February 25, February 28 and March 1, 2022. The actual fluctuation range of the share price after excluding the overall factors of the market is large. Please pay attention to the trading risks in the secondary market, make rational decisions and invest prudently.
The company solemnly reminds investors that the company’s information can be found on the website of Shanghai Stock Exchange (www.sse. Com. CN.) And the relevant announcements published in the securities times and Securities Daily, the information disclosure media designated by the company, please invest rationally and pay attention to investment risks.
4、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that, according to the relevant provisions of the Listing Rules of Shanghai Stock Exchange, the company currently has no matters that should be disclosed but not disclosed or the planning, negotiation, intention and agreement related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed according to the relevant provisions of the Listing Rules of Shanghai Stock Exchange Information that may have a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
It is hereby announced.
Zhejiang Ausun Pharmaceutical Co.Ltd(603229) board of directors March 2, 2022
